Literature DB >> 25431176

Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis.

Yasunori Omata1, Tetsuro Yasui, Jun Hirose, Naohiro Izawa, Yuuki Imai, Takumi Matsumoto, Hironari Masuda, Naoto Tokuyama, Shinya Nakamura, Shuichi Tsutsumi, Hisataka Yasuda, Kazuo Okamoto, Hiroshi Takayanagi, Atsuhiko Hikita, Takeshi Imamura, Koichi Matsuo, Taku Saito, Yuho Kadono, Hiroyuki Aburatani, Sakae Tanaka.   

Abstract

We have previously reported that transforming growth factor β (TGF-β) plays an essential role in receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis. However, the detailed underlying molecular mechanisms still remain unclear. Formaldehyde-assisted isolation of regulatory elements (FAIRE) and chromatin immunoprecipitation (ChIP) followed by sequencing (FAIRE-seq and ChIP-seq) analyses indicated the cooperation of Smad2/3 with c-Fos during osteoclastogenesis. Biochemical analysis and immunocytochemical analysis revealed that physical interaction between Smad2/3 and c-Fos is required for their nuclear translocation. The gene expression of nuclear factor of activated T-cells, cytoplasmic 1 (Nfatc1), a key regulator of osteoclastogenesis, was regulated by RANKL and TGF-β, and c-Fos binding to open chromatin sites was suppressed by inhibition of TGF-β signaling by SB431542. Conversely, Smad2/3 binding to Nfatc1 was impaired by c-Fos deficiency. These results suggest that TGF-β regulates RANKL-induced osteoclastogenesis through reciprocal cooperation between Smad2/3 and c-Fos.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CELL/TISSUE SIGNALING; CYTOKINES; MOLECULAR PATHWAYS; OSTEOCLAST; TRANSCRIPTION FACTORS

Mesh:

Substances:

Year:  2015        PMID: 25431176     DOI: 10.1002/jbmr.2418

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  17 in total

1.  Activin A receptor type 1-mediated BMP signaling regulates RANKL-induced osteoclastogenesis via canonical SMAD-signaling pathway.

Authors:  Maiko Omi; Vesa Kaartinen; Yuji Mishina
Journal:  J Biol Chem       Date:  2019-10-16       Impact factor: 5.157

2.  Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.

Authors:  Yaling Liu; Tulika Sharma; I-Ping Chen; Ernst Reichenberger; Yasuyoshi Ueki; Yumna Arif; Daniel Parisi; Peter Maye
Journal:  Bone       Date:  2018-03-09       Impact factor: 4.398

3.  Interspecies Single-Cell RNA-Seq Analysis Reveals the Novel Trajectory of Osteoclast Differentiation and Therapeutic Targets.

Authors:  Yasunori Omata; Hiroyuki Okada; Steffen Uebe; Naohiro Izawa; Arif B Ekici; Kerstin Sarter; Taku Saito; Georg Schett; Sakae Tanaka; Mario M Zaiss
Journal:  JBMR Plus       Date:  2022-05-16

4.  Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Authors:  Toshifumi Sugatani; Olga A Agapova; Yifu Fang; Alycia G Berman; Joseph M Wallace; Hartmut H Malluche; Marie-Claude Faugere; William Smith; Victoria Sung; Keith A Hruska
Journal:  Kidney Int       Date:  2016-09-22       Impact factor: 10.612

5.  Glucagon-like peptide 2 decreases osteoclasts by stimulating apoptosis dependent on nitric oxide synthase.

Authors:  Yi Lu; Dongdong Lu; Yu Hu
Journal:  Cell Prolif       Date:  2018-02-19       Impact factor: 6.831

Review 6.  Osteoclasts-Key Players in Skeletal Health and Disease.

Authors:  Deborah Veis Novack; Gabriel Mbalaviele
Journal:  Microbiol Spectr       Date:  2016-06

7.  Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice.

Authors:  Berno Dankbar; Michelle Fennen; Daniela Brunert; Silvia Hayer; Svetlana Frank; Corinna Wehmeyer; Denise Beckmann; Peter Paruzel; Jessica Bertrand; Kurt Redlich; Christina Koers-Wunrau; Athanasios Stratis; Adelheid Korb-Pap; Thomas Pap
Journal:  Nat Med       Date:  2015-08-03       Impact factor: 53.440

8.  Smad4 is required to inhibit osteoclastogenesis and maintain bone mass.

Authors:  Mayu Morita; Shigeyuki Yoshida; Ryotaro Iwasaki; Tetsuro Yasui; Yuiko Sato; Tami Kobayashi; Ryuichi Watanabe; Takatsugu Oike; Kana Miyamoto; Masamichi Takami; Keiko Ozato; Chu-Xia Deng; Hiroyuki Aburatani; Sakae Tanaka; Akihiko Yoshimura; Yoshiaki Toyama; Morio Matsumoto; Masaya Nakamura; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

9.  Identification of Nedd9 as a TGF-β-Smad2/3 Target Gene Involved in RANKL-Induced Osteoclastogenesis by Comprehensive Analysis.

Authors:  Yasunori Omata; Shinya Nakamura; Takuma Koyama; Tetsuro Yasui; Jun Hirose; Naohiro Izawa; Takumi Matsumoto; Yuuki Imai; Sachiko Seo; Mineo Kurokawa; Shuichi Tsutsumi; Yuho Kadono; Chikao Morimoto; Hiroyuki Aburatani; Takeshi Miyamoto; Sakae Tanaka
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

10.  GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation.

Authors:  Weiqing Liu; Liyan Zhou; Chenchen Zhou; Shiwen Zhang; Junjun Jing; Liang Xie; Ningyuan Sun; Xiaobo Duan; Wei Jing; Xing Liang; Hu Zhao; Ling Ye; Qianming Chen; Quan Yuan
Journal:  Nat Commun       Date:  2016-09-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.